Cullgen, a San Diego biotech that develops targeted protein degraders for unmet medical needs, raised $16 million in a Series A financing from two China investors, Sequoia Capital China and Highlight Capital. Cullgen said it would use the proceeds to develop ubiquitin-mediated, small molecule-induced protein degradation products, focusing on treatments for cancer, inflammatory and autoimmune diseases. The company also plans to discover novel E3 ligands that could become part of a targeted protein degrader complex. In 2018. Cullgen was seeded with $15 million from GNI Group. More details....
Stock Symbol: (TOKYO: 2160)
Share this with colleagues:
Original Article: Cullgen of San Diego Raises $16 Million in Series A from China Investors